Cargando…
Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831696/ https://www.ncbi.nlm.nih.gov/pubmed/29507532 http://dx.doi.org/10.1186/s12959-018-0161-9 |
_version_ | 1783303184122380288 |
---|---|
author | Abdel-Razeq, Hikmat Mansour, Asem Abdulelah, Hazem Al-Shwayat, Anas Makoseh, Mohammad Ibrahim, Mohammad Abunasser, Mahmoud Rimawi, Dalia Al-Rabaiah, Abeer Alfar, Rozan Abufara, Alaa’ Ibrahim, Alaa Bawaliz, Anas Ismael, Yousef |
author_facet | Abdel-Razeq, Hikmat Mansour, Asem Abdulelah, Hazem Al-Shwayat, Anas Makoseh, Mohammad Ibrahim, Mohammad Abunasser, Mahmoud Rimawi, Dalia Al-Rabaiah, Abeer Alfar, Rozan Abufara, Alaa’ Ibrahim, Alaa Bawaliz, Anas Ismael, Yousef |
author_sort | Abdel-Razeq, Hikmat |
collection | PubMed |
description | BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. METHODS: Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. RESULTS: A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). CONCLUSIONS: Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk. |
format | Online Article Text |
id | pubmed-5831696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58316962018-03-05 Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Abdel-Razeq, Hikmat Mansour, Asem Abdulelah, Hazem Al-Shwayat, Anas Makoseh, Mohammad Ibrahim, Mohammad Abunasser, Mahmoud Rimawi, Dalia Al-Rabaiah, Abeer Alfar, Rozan Abufara, Alaa’ Ibrahim, Alaa Bawaliz, Anas Ismael, Yousef Thromb J Research BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. METHODS: Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. RESULTS: A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). CONCLUSIONS: Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk. BioMed Central 2018-03-01 /pmc/articles/PMC5831696/ /pubmed/29507532 http://dx.doi.org/10.1186/s12959-018-0161-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Abdel-Razeq, Hikmat Mansour, Asem Abdulelah, Hazem Al-Shwayat, Anas Makoseh, Mohammad Ibrahim, Mohammad Abunasser, Mahmoud Rimawi, Dalia Al-Rabaiah, Abeer Alfar, Rozan Abufara, Alaa’ Ibrahim, Alaa Bawaliz, Anas Ismael, Yousef Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title_full | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title_fullStr | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title_full_unstemmed | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title_short | Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
title_sort | thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831696/ https://www.ncbi.nlm.nih.gov/pubmed/29507532 http://dx.doi.org/10.1186/s12959-018-0161-9 |
work_keys_str_mv | AT abdelrazeqhikmat thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT mansourasem thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT abdulelahhazem thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT alshwayatanas thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT makosehmohammad thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT ibrahimmohammad thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT abunassermahmoud thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT rimawidalia thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT alrabaiahabeer thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT alfarrozan thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT abufaraalaa thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT ibrahimalaa thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT bawalizanas thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook AT ismaelyousef thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook |